DOD Biotech Public Company Limited (DOD) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of DOD Biotech Public Company Limited THB 2.28, price THB 0.76, upside +200.0%, quality 56 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch DOD Biotech Public Company Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 0.7200 THB – 14.45 THB · fair‑value band 1.53 THB – 3.69 THB · the 0.7600 THB price screens below the 2.28 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow DOD Biotech Public Company in your weekly email
Every Wednesday you see whether DOD Biotech Public Company is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
DOD Biotech Public Company Limited, together with its subsidiaries, manufactures and distributes dietary supplements in Thailand. It offers dietary supplements for beauty and health in various forms comprising capsules, gels, jellies, powder, shot drinks, soft gels, tablets, probiotics, gummies, and direct-to-mouth.
Show more
DOD Biotech Public Company Limited, together with its subsidiaries, manufactures and distributes dietary supplements in Thailand. It offers dietary supplements for beauty and health in various forms comprising capsules, gels, jellies, powder, shot drinks, soft gels, tablets, probiotics, gummies, and direct-to-mouth. The company also provides food supplements and health drinks. In addition, it offers advisory, trading, and supplementary services; and research and development, design, FDA and HALAL registration, and consulting services. DOD Biotech Public Company Limited was incorporated in 2011 and is based in Mueang Samut Sakhon, Thailand.
Stock analysis
DOD Biotech Public Company Limited (DOD) currently trades at 0.7600 THB, while our model-based Fair Value estimate is 2.28 THB, implying the stock looks roughly 66.7% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 6.06 THB per share, and 22 of the 24 models we run sit above the 0.7600 THB price.
Bear case: the Economic Profit group reads lowest at 0.7300 THB, and 2 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: 1.53 THB (bear) to 3.69 THB (bull), the price of 0.7600 THB sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Consumer Defensive sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
DOD Biotech Public Company Limited reported revenue of 609M THB in FY2025 versus 1.0B THB in FY2021, a compound −12.0%/yr. Reported net income was 59.6M THB in FY2025, compounding −28.9%/yr from FY2021.
Key figures
Market cap 522M THB (≈ $15.6M) · P/E ratio 25.3 · P/S ratio 2.48 · EPS (TTM) 0.0300 THB · Dividend yield 6.6% · Net margin 9.8% · Return on equity 1.4% · Return on assets (EBIT) 5.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 62% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −3% fair-value upside, at 200%, DOD screens cheaper than that median.
Fair Value models
Bear 1.53 THBFair Value 2.28 THBBull 3.69 THB
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−5.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−17.7%
Start year 2020 (pandemic). Over 10 years: +13.6% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+60.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in THB ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in THB: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−10.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−17.4%
Dividend (yield on the price)6.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−17% vs −5%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 4%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−24.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Thailand: IMF forecast 1.2% a year to 2030, 1.1% from 2016 to 2025) that is about −24.9% a year for the price.
Compare DOD Biotech Public Company Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 668 stocks
Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside+200% · Top 25%
Profitability
Return on equity (TTM)1% · Below median
Return on assets1% · Bottom 25%
Net margin (TTM)2% · Below median
Operating margin (TTM)−10% · Bottom 25%
Growth and dividend
Revenue growth−29% · Bottom 25%
Dividend yield (TTM)6.6% · Top 25%
Balance sheet
Debt / equity0.06× · Below median
Valuation Multiplesvs Packaged Foods median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "DOD Biotech Public Company Limited Fair Value". https://www.fairvalue-calculator.com/stock/DOD
Frequently asked questions
Is DOD Biotech Public Company Limited (DOD) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 2.28 THB versus a price of 0.7600 THB, about +200% upside (undervalued).
What is the fair value of DOD?
Our model-based fair value for DOD Biotech Public Company Limited is 2.28 THB (as of Sep 24, 2026), built from audited fundamentals. The current price: 0.7600 THB.
What is the quality score of DOD?
DOD Biotech Public Company Limited has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DOD Biotech Public Company Limited (DOD)?
Our model-based price target is the fair value of 2.28 THB (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 1.53 THB, optimistic scenario 3.69 THB. It is a calculation from audited fundamentals, not an analyst target.
What is the DOD Biotech Public Company Limited stock forecast for 2026?
Our models put fair value at 2.28 THB, about +200% upside versus a price of 0.7600 THB (undervalued). Cautious scenario 1.53 THB, optimistic scenario 3.69 THB. The calculation is refreshed regularly with new filings.
What is the revenue of DOD Biotech Public Company Limited (DOD)?
DOD Biotech Public Company Limited reported trailing-twelve-month revenue of about 571M THB (latest available figure, as of Sep 24, 2026).
Does DOD Biotech Public Company Limited pay a dividend?
DOD Biotech Public Company Limited currently shows a dividend yield of about 6.58% relative to its recent price (as of Sep 24, 2026).
What growth is priced into DOD Biotech Public Company Limited (DOD)?
For today's price to be fair in a discounted-cash-flow model, DOD Biotech Public Company Limited would have to grow free cash flow by -24.0 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -17.7 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of DOD use?
Our models discount DOD Biotech Public Company Limited at 11.0 %: a base by market capitalisation (nano), damped by beta 0.80, country premium for Thailand. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DOD Biotech Public Company Limited that is -24.0 % per year a year over ten years, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has DOD Biotech Public Company Limited (DOD) delivered so far?
Over the past 5 years revenue at DOD Biotech Public Company Limited grew -17.7 % a year. The price currently implies -24.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DOD Biotech Public Company Limited (DOD) growing?
The median revenue growth in the sector is +2.9 % a year. That is the yardstick for the growth priced into DOD Biotech Public Company Limited (-24.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DOD Biotech Public Company Limited (DOD)?
The free-cash-flow yield on the price is 12.40 %: that much free cash flow DOD Biotech Public Company Limited produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DOD Biotech Public Company Limited (DOD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DOD Biotech Public Company Limited it is 2.28 THB per share (as of Sep 24, 2026), against a price of 0.7600 THB. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is DOD Biotech Public Company Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, DOD trades below its calculated fair value: price 0.7600 THB, fair value 2.28 THB, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DOD?
No. The price is what the market pays today (0.7600 THB); the fair value is what the company's own numbers justify (2.28 THB). For DOD Biotech Public Company Limited the two are 1.52 THB per share apart. That gap is exactly why we show both numbers side by side.
How much is DOD Biotech Public Company Limited worth?
The market values DOD Biotech Public Company Limited at about 522M THB (market capitalisation, as of Sep 24, 2026). Per share that is 0.7600 THB; our models calculate a fair value of 2.28 THB per share.
What do the bullish and bearish scenarios say about DOD?
Our models span a range for DOD Biotech Public Company Limited: cautious scenario 1.53 THB, base 2.28 THB, optimistic 3.69 THB per share (as of Sep 24, 2026, price 0.7600 THB). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DOD?
DOD Biotech Public Company Limited trades at a price-to-earnings ratio of 25.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 2.28 THB is built from several models across several years. Other multiples: P/B 0.6, P/S 0.9, EV/EBITDA 8.8.
How solid is the balance sheet of DOD Biotech Public Company Limited (DOD)?
Balance-sheet figures for DOD Biotech Public Company Limited (as of Sep 24, 2026): return on equity 1.4%, debt of 0.06 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is DOD from its 52-week high?
DOD Biotech Public Company Limited trades at 0.7600 THB, about 62% below its 52-week high of 2.00 THB and 6% above the low of 0.7200 THB (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 2.28 THB is for.
Which stocks are comparable to DOD Biotech Public Company Limited?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, The Kraft Heinz Company, Foshan Haitian Flavouring and Food Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DOD Biotech Public Company Limited stock attractive at the current price?
The data as of Sep 24, 2026: price 0.7600 THB, calculated fair value 2.28 THB (+200%), Quality Score 56/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DOD calculated?
We run DOD Biotech Public Company Limited through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2.28 THB, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. DOD Biotech Public Company Limited currently trades 200 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DOD Biotech Public Company Limited (DOD)?
The closing price on Sep 24, 2026 was 0.7600 THB. Our model-based fair value is 2.28 THB, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DOD Biotech Public Company Limited right now?
The price is below even our cautious bear case (1.53 THB). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (56/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (1.53 THB to 3.69 THB) leaves room in how you read the outcome.
Where does the earnings growth of DOD Biotech Public Company Limited (DOD) come from?
Earnings per share at DOD Biotech Public Company Limited grew −11.6 % a year from 2015 to 2025. Broken into its drivers: revenue per share +9.5 %, EBIT margin −17.1 %, tax rate −3.0 %, residual (interest, one-offs) +0.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of DOD Biotech Public Company Limited
How large is the market capitalisation of DOD Biotech Public Company Limited (DOD)?
The market capitalisation of DOD Biotech Public Company Limited is 522M THB (≈ $15.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DOD Biotech Public Company Limited (DOD)?
The price-to-sales ratio of DOD Biotech Public Company Limited is 2.48 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DOD Biotech Public Company Limited (DOD)?
Earnings per share at DOD Biotech Public Company Limited are 0.0300 THB (price ÷ EPS = P/E 25.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of DOD Biotech Public Company Limited (DOD)?
The dividend yield of DOD Biotech Public Company Limited is 6.6% (payout 167%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DOD Biotech Public Company Limited (DOD)?
The net margin of DOD Biotech Public Company Limited is 9.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DOD Biotech Public Company Limited (DOD)?
The return on equity (ROE) of DOD Biotech Public Company Limited is 1.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DOD Biotech Public Company Limited (DOD)?
On an EBIT basis the return on assets of DOD Biotech Public Company Limited is 5.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DOD Biotech Public Company Limited (DOD)?
The operating margin of DOD Biotech Public Company Limited is −10.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DOD Biotech Public Company Limited (DOD)?
Revenue at DOD Biotech Public Company Limited is growing −29.3% versus a year earlier (3y avg +4.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DOD Biotech Public Company Limited (DOD)?
Earnings per share at DOD Biotech Public Company Limited are growing +206% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does DOD Biotech Public Company Limited (DOD) hold?
DOD Biotech Public Company Limited holds more cash than debt, 58.9M THB net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch DOD Biotech Public Company Limited in the live analysis
One click puts DOD Biotech Public Company Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
